Jul, 11 2018 16:32 JST

Source: Eisai

Eisai: Oral Antifungal Agent Nailin Capsules 100mg to be Launched in Japan


TOKYO, Jul, 11 2018 - (JCN Newswire) - Sato Pharmaceutical Co., Ltd. and Eisai Co., Ltd. will launch the oral antifungal agent NAILIN Capsules 100mg in Japan on July 27, 2018.

Sato Pharmaceutical obtained marketing and manufacturing approval for NAILIN Capsules 100mg as an oral treatment for onychomycosis. This product is the first new treatment for the disease in approximately 20 years. NAILIN Capsules 100mg contains the active ingredient fosravuconazole L-lysine ethanolate which was discovered by Eisai and has improved bioavailability compared to ravuconazole.

Caused by the invasion of the nails by the Trichophyton fungus via the skin of the hands and feet, onychomycosis is a fungal infection that induces symptoms such as the clouding and thickening of nails as well as hyperkeratosis in the area surrounding the nail. Onychomycosis affects 1 in every 10 Japanese people with an estimated approximately 11 million sufferers in Japan, and incidence rises with age. Although it is an easy disease to leave untreated as it is not associated with pain or itchiness, if the disease progresses, various symptoms may occur such as pain from misshapen nails, difficulty in putting on shoes and pain upon walking, and many patients are concerned about reduction in QOL (quality of life). Furthermore, it is possible for Trichophyton to infect other people by sharing slippers, bathmats and other mediums.

In a Phase III clinical study conducted by Sato Pharmaceutical of NAILIN Capsules 100mg administered orally once daily for 12 weeks in patients with onychomycosis conducted in Japan, superior efficacy was confirmed for NAILIN Capsules 100mg compared to placebo.

Going forward, Sato Pharmaceutical will conduct marketing of NAILIN Capsules 100mg, while Sato Pharmaceutical and Eisai are jointly providing information on its proper use. By expanding the options for treating onychomycosis through NAILIN Capsules 100mg, the two companies are striving to further contribute to the treatment of onychomycosis patients.

About Sato Pharmaceutical Co., Ltd.

Sato Pharmaceutical Co., Ltd., operating under its corporate philosophy of "Healthcare Innovation", is a pharmaceutical company that provides effective, safe, and highquality products for practicing selfcare, while always keeping the health of its customers in mind. In addition to its main consumer healthcare business, Sato Pharmaceutical also develops and provides highly original products primarily in the field of dermatology.

Regarding ethical pharmaceuticals, through the marketing of NAILIN Capsules 100 mg in addition to the onychomycosis treatment LUCONAC Solution 5% launched on April 25, 2016, Sato Pharmaceutical is able to provide both externally and internally administered medicines as options for the treatment of onychomycosis. Going forward, Sato Pharmaceutical is expanding promotion aimed at establishing a brand with these products as two pillars of onychomycosis treatment, and is striving to continue growing as a leading company in the treatment of onychomycosis that is trusted by healthcare professionals.


About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our human health care philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Oncology and Neurology.

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com.


Contact:
Sato Pharmaceutical Co., Ltd.
Public Relations Department 
+81-(0)3-5412-7354

Eisai Co., Ltd.
Public Relations Department 
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech, HealthCare

Copyright ©2018 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai And Merck & Co. Announce China NMPA Approval of First Approval for LENVIMA (Lenvatinib) for Treatment of Unresectable HCC
September 05 2018 14:28 JST
 
Eisai Receives Approval for Partial Label Change for Vascular Embolization Device DC Bead
September 03 2018 14:50 JST
 
Eisai's LENVIMA (LENVATINIB) Capsules Approved for First-Line Treatment of Unresectable Hepatocellular Carcinoma (HCC) in South Korea
August 30 2018 09:36 JST
 
Biogen and Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimer's Disease Treatment Aducanumab
August 29 2018 10:25 JST
 
Eisai: Long-Term Cardiovascular Outcomes Data for Anti-Obesity Agent BELVIQ
August 28 2018 09:11 JST
 
Eisai: European Commission Grants Marketing Authorization for LENVIMA (Lenvatinib)
August 23 2018 08:00 JST
 
Eisai Signs Collaboration Agreement for Anti-Obesity Agent Lorcaserin in China to CY Biotech
July 31 2018 14:13 JST
 
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Announce U.S. FDA Grants Breakthrough Therapy Designation for LENVIMA
July 31 2018 10:27 JST
 
Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer's Disease at AAIC 2018
July 26 2018 10:34 JST
 
Eisai and Biogen Present Detailed Results from Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer's Disease at AAIC 2018
July 26 2018 08:01 JST
 
More Press release >>

Latest Press Release


More Latest Release >>